At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
AUPH Aurinia Pharmaceuticals
Market Closed 05-15 16:00:00 EDT
15.28
-0.56
-3.54%
盘后15.20
-0.08-0.52%
19:42 EDT
High15.78Low15.14Vol1.11M
Open15.56D1 Closing15.84Amplitude4.01%
Mkt Cap1.97BTradable Cap1.96BTotal Shares128.60M
T/O17.09MT/O Rate0.87%Tradable Shares128.00M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Aurinia Pharmaceuticals Completes Acquisition of Kezar Life Sciences
TIPRANKS  ·  05-11
Aurinia Pharmaceuticals Completes Acquisition of Kezar Life Sciences
Aurinia Pharmaceuticals Inc reports results for the quarter ended March 31 - Earnings Summary
Reuters  ·  05-11
Aurinia Pharmaceuticals Inc reports results for the quarter ended March 31 - Earnings Summary
Aurinia completes Kezar acquisition at $6.96 per share plus CVR
Reuters  ·  05-11
Aurinia completes Kezar acquisition at $6.96 per share plus CVR
Kezar Q1 net loss narrows to $5.8 million; operating loss narrows to $7.4 million
Reuters  ·  05-11
Kezar Q1 net loss narrows to $5.8 million; operating loss narrows to $7.4 million
Aurinia publishes corporate presentation on LUPKYNIS growth strategy in lupus nephritis
Reuters  ·  05-07
Aurinia publishes corporate presentation on LUPKYNIS growth strategy in lupus nephritis
Earnings Flash (AUPH) Aurinia Pharmaceuticals Posts Q1 EPS $0.25, vs. FactSet Est of $0.20
MT Newswires Live  ·  05-07
Earnings Flash (AUPH) Aurinia Pharmaceuticals Posts Q1 EPS $0.25, vs. FactSet Est of $0.20
Aurinia Q1 net income rises 48% to $34.4 million; revenue climbs 24% to $77.7 million
Reuters  ·  05-07
Aurinia Q1 net income rises 48% to $34.4 million; revenue climbs 24% to $77.7 million
BRIEF-Aurinia Pharmaceuticals Q1 Product Revenue USD 73.563 Million
Reuters  ·  05-07
BRIEF-Aurinia Pharmaceuticals Q1 Product Revenue USD 73.563 Million
Aurinia Pharmaceuticals Inc: Reiterates Its Guidance for 2026 Total Revenue of $315 Mln to $325 Mln
THOMSON REUTERS  ·  05-07
Aurinia Pharmaceuticals Inc: Reiterates Its Guidance for 2026 Total Revenue of $315 Mln to $325 Mln
Aurinia Pharmaceuticals Q1 Pretax Profit USD 43.925 Million
THOMSON REUTERS  ·  05-07
Aurinia Pharmaceuticals Q1 Pretax Profit USD 43.925 Million
Aurinia Pharmaceuticals Q1 Operating Income USD 41.422 Million
THOMSON REUTERS  ·  05-07
Aurinia Pharmaceuticals Q1 Operating Income USD 41.422 Million
Press Release: Aurinia Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2026 and Provides Update on Recent Business Progress
Dow Jones  ·  05-07
Press Release: Aurinia Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2026 and Provides Update on Recent Business Progress
Calendar of U.S. Earnings Expected in the Week Ahead
Dow Jones  ·  04-30
Calendar of U.S. Earnings Expected in the Week Ahead
Aurinia Pharmaceuticals announces annual shareholder meeting
Reuters  ·  04-22
Aurinia Pharmaceuticals announces annual shareholder meeting
A Look At Aurinia Pharmaceuticals (AUPH) Valuation After Its Recent Leadership Overhaul
Simply Wall St.  ·  04-06
A Look At Aurinia Pharmaceuticals (AUPH) Valuation After Its Recent Leadership Overhaul
Aurinia Pharma to buy Kezar Life Sciences for $6.955 a share plus CVR
Reuters  ·  04-04
Aurinia Pharma to buy Kezar Life Sciences for $6.955 a share plus CVR
Aurinia Pharmaceuticals CFO Michael Hearne files initial beneficial ownership statement
Reuters  ·  04-03
Aurinia Pharmaceuticals CFO Michael Hearne files initial beneficial ownership statement
Aurinia Pharma COO Ryan Cole files initial beneficial ownership statement
Reuters  ·  04-03
Aurinia Pharma COO Ryan Cole files initial beneficial ownership statement
Analysts Offer Insights on Healthcare Companies: Terns Pharmaceuticals (TERN) and Aurinia Pharmaceuticals (AUPH)
TIPRANKS  ·  03-31
Analysts Offer Insights on Healthcare Companies: Terns Pharmaceuticals (TERN) and Aurinia Pharmaceuticals (AUPH)
Kezar Life Sciences takeover valuation ‘makes sense,’ says Jefferies
TIPRANKS  ·  03-31
Kezar Life Sciences takeover valuation ‘makes sense,’ says Jefferies

Introduction

Company Name.
Aurinia Pharmaceuticals
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. The company also offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. Aurinia Pharmaceuticals Inc. is headquartered in Victoria, Canada.
Issue price:
--